Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 21Radiosurgery 20Radiotherapy 17Androgen Antagonists 14Leuprolide 12Goserelin 12bicalutamide 11Prednisone 9Gonadotropin-Releasing Hormone 9Abiraterone Acetate 9enzalutamide 8Surveys and Questionnaires 8Radiotherapy, Intensity-Modulated 8Brachytherapy 8Blood Specimen Collection 8acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 7Triptorelin Pamoate 7Multiparametric Magnetic Resonance Imaging 7abiraterone 5pembrolizumab 4cabazitaxel 4Standard of Care 4Positron Emission Tomography Computed Tomography 4Metformin 4Heavy Ion Radiotherapy 4Flutamide 4Exercise 4Estramustine 4luprolide acetate gel depot 3darolutamide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Prostatic Neoplasms × Indomethacin × Clear all
NCT02935205 2023-11-29

Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer

University of California, Davis

Phase 1/2 Unknown
38 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡